Methyleugenol-a natural constituent of herbs and spices-is hepatocarcinogenic in rodent models. It can form DNA adducts after side-chain hydroxylation and sulfation. We previously demonstrated that human sulfotransferases (SULTs) 1A1 and 1A2 as well as mouse Sult1a1, expressed in Salmonella target strains, are able to activate 1′-hydroxymethyleugenol (1′-OH-ME) and 3′-hydroxymethylisoeugenol (3′-OH-MIE) to mutagens. Now we investigated the role of these enzymes in the formation of hepatic DNA adducts by methyleugenol in the mouse in vivo. -(transmethylisoeugenol-3′-yl)-2′-deoxyadenosine. Thus, the adduct formation by both compounds was nearly completely dependent on the presence of SULT1A enzymes, with human SULT1A1/2 producing stronger effects than mouse Sult1a1. Moreover, a dose of 0.05 mg/kg methyleugenol (one-fourth of the estimated average daily exposure of humans) was sufficient to form detectable adducts in humanized (ko-tg) mice. Although 3′-OH-MIE was equally mutagenic to 1′-OH-ME in Salmonella strains expressing human SULT1A1 or 1A2, it only formed 0.14% of hepatic adducts in ko-tg mice compared with an equimolar dose of 1′-OH-ME, suggesting an important role of detoxifying pathways for this isomer in vivo.
Introduction
Alkenylbenzenes are secondary metabolites occurring in many herbs and spices (e.g. basil and pimento) (1, 2) as well as in essential oils used for flavoring foods and cosmetics (3) . Some alkenylbenzenes, such as methyleugenol (structural formula in Figure 1 ) and safrole, have shown carcinogenic activity in rat and mouse models, the liver being the principal target organ (4) (5) (6) (7) (8) . The carcinogenicity of alkenylbenzenes is associated with the formation of DNA adducts (6, (9) (10) (11) . In general, 1′-hydroxylated metabolites of alkenylbenzenes were stronger carcinogens (9, (12) (13) (14) and genotoxicants than the parent compounds (15, 16) . In addition, sulfotransferases (SULTs) are involved in the activation of alkenylbenzenes. This was best demonstrated for the in vivo situation with safrole. The SULT inhibitor pentachlorophenol and the usage of brachymorphic mice, characterized by a reduced synthesis of the SULT cofactor 3′-phosphoadenosine-5′-phosphosulfate (17) , strongly decreased hepatic DNA adduct and tumor formation in rodents treated with 1′-hydroxysafrole or safrole (4, 10, 18, 19) . The role of individual SULT forms was studied in vitro using recombinant Salmonella typhimurium TA100 strains in mutagenicity studies with 1′-hydroxymethyleugenol (1′-OH-ME) and 3′-hydroxymethylisoeugenol (3′-OH-MIE) (20) . Among the human enzymes, SULT1A1 was most efficient in the activation of both metabolites. Moreover, SULT1A1 is the most abundant SULT form in the human organism. It is highly expressed in the liver but also present in many extrahepatic tissues (21, 22) . Some activation was also observed with human SULT1A2, 1C2 and 1E1. The expression levels of these forms are usually much lower than that of SULT1A1 in human tissues. The SULT1A2 gene is located next to the SULT1A1 gene, as a result of recent gene duplication in primates (23) . Among the mouse Sult forms studied, Sult1a1 was most effective in the activation of 1′-OH-ME and 3′-OH-MIE, although it did not reach the efficiency of its human ortholog (20) . The SULT-dependent mutagenicity of 1′-OH-ME and 3′-OH-MIE was accompanied by the formation of DNA adducts in the target bacterial cells. Using mass spectrometry and nuclear magnetic resonance spectroscopy, we identified the major adduct as N 2 -(transmethylisoeugenol-3′-yl)-2′-deoxyguanosine (N 2 -MIE-dG); a second adduct, formed at a nearly 50-fold lower level, was identified as N 6 -(trans-methylisoeugenol-3′-yl)-2′-deoxyadenosine (N 6 -MIE-dA) (20) . The structural formulas of these adducts are presented in Figure 1 . We devised ultra-performance liquid chromatography-tandem mass spectrometry methods with isotopic-labeled internal standards for the specific and sensitive detection of these adducts (20, 24, 25) .
We recently reported the construction and characterization of mouse lines transgenic for the human SULT1A1-SULT1A2 gene cluster (26) . In the meantime, we also constructed Sult1a1 knockout (ko) mice. From these lines, we bred humanized mice for these genes, lacking a functional mouse Sult1a1 but containing the human SULT1A1-SULT1A2 gene cluster.
The aim of this study was to explore the role of mouse and human SULT1A enzymes in the formation of hepatic DNA adducts by methyleugenol in an in vivo model. In addition to methyleugenol, we used its metabolites 1′-OH-ME and 3′-OH-MIE as well as methylisoeugenol, another alkenylbenzene metabolized to 3′-OH-MIE (27, 28) .
Materials and methods

Chemicals and enzymes
Methyleugenol, methylisoeugenol, tricaprylin, micrococcal nuclease from Staphylococcus aureus, phosphodiesterase (type II) from bovine spleen and alkaline phosphatase from calf intestine were obtained from Sigma-Aldrich (Taufkirchen, Germany). Phosphodiesterase (type II) from calf spleen was purchased from Merck (Darmstadt, Germany (20) . 1′-OH-ME was synthesized as described by Cartus et al. (29) .
Mouse lines and their maintenance
Wild-type FVB/N mice (subsequently termed wt mice) were purchased from Harlan (Borchen, Germany). The generation of transgenic FVB/N mice with multiple copies of the human SULT1A1-SULT1A2 gene cluster integrated in Abbreviations: 1′-OH-ME, 1′-hydroxymethyleugenol; 3′-OH-MIE, 3′-hydroxymethylisoeugenol; dN, 2′-deoxyribonucleoside(s); ko, Sult1a1 knockout; kotg, Sult1a1 knockout mice transgenic for human SULT1A1/2; LOD, limit of detection;
-(trans-methylisoeugenol-3′-yl)-2′-deoxyguanosine; SULT, sulfotransferase; tg, transgenic for human SULT1A1/2; wt, wild-type.
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chromosome 9 is described elsewhere (26) . The line termed tg1 in the original study was used. The construction of mSult1a1 knockout mice in the FVB/N background is described in Targeting vector construction and homologous recombination creating a defective mSult1a1 gene and Generation of mSult1a1 null mutant mice and their breeding with hSULT1A1/2 transgenic mice.
The homozygous transgenic line was bred with wt mice to generate animals with a hemizygous gene status with respect to the human transgene (subsequently termed tg mice). The transgenic line tg1 was bred with ko mice to generate a line homozygous for both traits. For the present study, they were bred with ko mice to obtain animals hemizygous for the transgene and homozygous for the knockout (subsequently termed ko-tg mice).
Targeting vector construction and homologous recombination creating a defective mSult1a1 gene
For construction of the targeting vector, the Sult1a1-bearing bacterial artificial chromosome RP23-421P23 (RZPD, Berlin, Germany) was subcloned 
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into a minimal vector derived from pACYC177 (NEB, Ipswich, MA) by Red/ET recombination in Escherichia coli DH10β cells with the Quick and Easy Bacterial Artificial Chromosome Modification Kit (Genebridges, Heidelberg, Germany) according to the manufacturer's instructions. For PCR-mediated amplification of pACYC177, the oligonucleotides 5′-ATA-AAT-ATT-AAA-CAT-TTA-TAT-GAT-ACA-TAA-GAA-ACA-GTA-TGG-TGT-TGA-CTC-GAG-TGA-AGA-CGA-AAG-GGC-CTC-GTG-3′ and 5′-AAC-AGC-CAG-CCA-CCT-CCA-TTA-GAA-GCA-CAC-CAC-TAC-CAT-TTG-AGG-TGC-TCG-AGC-GCT-AGC-GGA-GTG-TAT-ACT-GGC-3′ (further information in Supplementary Table S-I, available at Carcinogenesis Online) were used containing XhoI restriction sites (underlined) for restriction analysis and targeting DNA identification. The neomycin cassette was amplified by PCR from the plasmid pGK-gb2-Neo (kind gift from F.Stewart, TU Dresden, Germany) using the oligonucleotides 5′-ATC-GGA-GCC-CTT-CCA-GAG-TGA-CAG-CCA-GTA-ACC-CTC-CAT-ATG-AGA-TGA-AAT-AGG-GCT-TGA-ATA-G-3′ and 5′-GGA-CTA-TGT-ATG-CTT-GGG-CAC-TAG-GGA-CAT-GGA-ACA-ATG-TTC-CAC-AGG-TGA-TCA-GAC-ATA-GCA-CAG-TGG-TG-3′ and subsequently taken for Red/ET recombination in order to exchange the region of exons 2-4 of the mSult1a1 gene within the targeting vector. Colony-PCR and subsequent sequencing of the integration sites checked successful Red/ET recombination. For primer sequences and PCR conditions, see Supplementary Table S-I, available at Carcinogenesis Online. Recombination in F1 C57Bl/6x129/Sv embryonic stem cells (T.Hiiragi, unpublished) was performed using 10 µg of XhoI-digested and purified vector DNA using standard embryonic stem cell procedures (30) . Genotyping of selected embryonic stem cell clones was performed by Southern blot analysis using SacI-digested genomic DNA using standard procedures (31) . The DNA probe for hybridization was amplified by PCR from mouse genomic DNA using the primers 5′-AAA-GCA-GGT-TGT-AGC-CAG-3′ and 5′-TAC-ATA-AGA-AAC-AGT-ATG-3′. The PCR product was 32 P-labeled using the Random Primed Labeling Kit (Roche, Basel, Switzerland) according to the manufacturer's protocol.
Generation of mSult1a1 null mutant mice and their breeding with hSULT1A1/2 transgenic mice
We generated chimerical mice from successfully recombined embryonic stem cell clones by blastocyst injection according to standard procedures (30) . Recipient C57BL/6J embryos were isolated as morulae from superovulated females 2.5 days post coitum and cultivated in vitro to the blastocyst stage using M16 medium (Sigma-Aldrich). Embryo transfer after blastocyst injection was carried out into oviducts of pseudo-pregnant NMRI mice. High-contribution male chimeras were mated to FVB/N females. Mice showing germ line transmission of the mutant Sult1a1 allele were backcrossed to FVB/N animals. Using markerassisted backcrossing (Charles Rivers, Troy, MI), 99.3% homozygosity (except the region around the Sult1a1 gene) in an FVB/N genetic background was reached after five generations. Mice from this generation were bread together to establish a homozygous FVB/N ko mouse line. Likewise, homozygous hSULT1A1/2 transgenic mice were bred with homozygous mSult1a1 knockout mice for two generations to establish a mouse line being homozygous for both, the hSULT1A1/2 transgene and the murine mSult1a1 knockout.
Treatment of animals
All animal experiments presented herein were approved by Landesamt für Umwelt, Gesundheit und Verbraucherschutz of the State of Brandenburg under the number V3-2347-15-2012 or 23-2347-18-2009Ä2. They were maintained under timed lighting conditions. They received water and semisynthetic diet (Altromin C1000 pellets, Altromin, Lage, Germany) ad libitum. Male mice of an age of 8-10 weeks were used. Methyleugenol and methylisoeugenol were administered by gavage using tricaprylin (1.7 ml/kg body mass). The highest dose was 50 mg (280 µmol) per kg body mass. 1′-OH-ME and 3′-OH-MIE were administered at equimolar doses in the same vehicle. However, the intraperitoneal route was used for the following reasons: (i) these compounds do not occur in foodstuff but are metabolically formed in the liver and other tissues from methyleugenol or methylisoeugenol; this toxicokinetic situation is better mimicked by intraperitoneal, rather than oral, treatment and (ii) moreover, various allylic and benzylic alcohols are acid labile and, therefore, may be chemically altered in the stomach after oral treatment.
In the initial experiments, animals were killed at varying times after the treatment. In the subsequent experiments, they were killed 6 h after the treatment (which is in the plateau phase of the time course curve of the adducts). Each experiment comprised several negative control animals treated only with the vehicle tricaprylin.
Analysis of DNA adducts
In general, nucleic acids were isolated from liver homogenates using the standard phenol-chloroform extraction (32). They were quantified spectrophotometrically using a Nanodrop ND-1000 Spectrophotometer (peQlab, Erlangen, Germany). In the standard method for adduct analysis, aliquots of 12.5 µg nucleic acids, spiked with isotope-labeled adduct standards, were digested to nucleosides using phosphodiesterase type II, micrococcal nuclease and alkaline phosphatase, as described previously (24) . However, when only low adduct levels were expected or the first analysis provided a negative result or low adduct levels, the enhanced method was used. For this purpose, the amounts of nucleic acids and enzymes used were increased by a factor of 9, and a butanol extraction step was introduced after the digestion in order to enrich analytes (and internal standards) and to remove disturbing material (25) . In some cases, the enhanced method was used with DNA isolated on Qiagen columns (Qiagen, Hilden, Germany), rather than phenol-chloroform extraction. However, the mode of DNA isolation had negligible impact on the adduct levels determined and the assay sensitivity.
We recently detected that enzymatic digests of DNA prepared by the phenolchloroform extraction contain substantial levels of ribonucleosides in addition to 2′-deoxyribonucleosides (dN), despite treatment with RNase prior to the extraction (25) . Ribonucleosides, although at much lower levels, were also found in digests of DNA isolated on Qiagen columns. Fortunately, our analytical method is specific for dN adducts, with no risk of mixing up with ribonucleoside adducts. However, in order to determine the actual level of DNA, we directly determined the level of dG in the hydrolysate. To this end, we spiked small samples of the digests (the equivalent of 24 ng of nucleic acid, omitting the butanol extraction step) with the internal standard [ 15 N 5 ]dG (2 pmol) and subjected it to liquid chromatography-tandem mass spectrometry analysis. The total number of dN molecules was calculated knowing that 2′-deoxyguanosine constitutes 21% of all dN in the genomic DNA of the mouse (33) .
Adduct and dG levels in the digests were determined with an Acquity UPLC system equipped with an Acquity BEH-Phenyl column (1.7 µm, 2.1 × 100 mm) and connected to a Xevo TQ triple quadrupole mass spectrometer (all from Waters, Eschborn, Germany). Analytes were ionized by an electrospray source operating in the positive ion mode. The m/z transitions 428.1 → 177.2 (loss of dA) and 444.1 → 328.2 (loss of deoxyribose) were used for quantifying N 6 -MIE-dA and N 2 -MIE-dG, respectively (20) . Additional m/z transitions were used as qualifiers (20) . Likewise the m/z transition 268.2 → 152.1 (loss of deoxyribose) was used for quantifying dG. Qualifier transitions and settings of the mass spectrometer are given in Supplementary Table S-II, available at Carcinogenesis Online.
Determination of the limit of detection
The limit of detection (LOD) is determined by noise signals that are dependent on the source of the DNA and the sample preparation. It was defined as the adduct level giving a peak area of the quantifier that was the mean plus three times the standard deviation from 6 to 10 separate digests of hepatic DNA from untreated mice.
Microsomal metabolism of methyleugenol
Microsomal biotransformation of methyleugenol was studied as described elsewhere (29) with minor modification. Briefly, hepatic microsomal fractions were prepared from negative control animals used in the DNA adduct studies, individually from four mice of each line. The protein content was measured photometrically using the bicinchoninic acid assay (Pierce, Rockford, IL). Incubation mixtures in a final volume of 100 µl contained microsomal protein (0.1 mg), methyleugenol (200 µM), acetonitrile (1%, solvent used for adding methyleugenol) and a reduced nicotinamide adenine dinucleotide phosphateregenerating system. Incubations were performed at 37°C with gentle shaking for 1 h. The reaction was terminated and protein was precipitated by adding acetone, containing 3,4-dimethoxypropylbenzene as internal standard. The metabolites were analyzed using an Agilent 1100 HPLC system equipped with an autosampler (G1329A), a quadruple pumping system (G1311A), a diode array spectrophotometer (DAD G1315A) and a column heater (G1316A; all from Agilent, Waldkirch, Germany). The separations were performed on a C18 column (Highbar®, 5 µm, 4.0 mm × 125 mm, LiChrosorb®, Merck). The mobile phase system consisted of solvent A (10 mM ammonium acetate in water) and solvent B (methanol). Separation was achieved using a 30 min linear gradient to 70% B from initial conditions of 10% B, following a 5 min period with constant eluent composition of 70% B with a total analysis time of 38 min per sample at a flow rate of 1 ml/min. The column temperature was kept constantly at 35°C and detection wavelengths were 230, 261 and 280 nm. Metabolite standards, chemically prepared as described previously (29), were used for the calibration.
Results and discussion
Influence of SULT status on phase I metabolism of methyleugenol
Incubation of methyleugenol with hepatic reduced nicotinamide adenine dinucleotide phosphate-fortified microsomes from wt, ko, tg and ko-tg mice yielded similar levels and patterns of metabolites (Figure 2 and Table I ). The proximate genotoxicants 1′-OH-ME and 3′-OH-MIE constituted nearly 53 and 12% of the metabolites detected in all cases. Thus, genetic manipulation of the SULT status did not affect the cytochrome P450-mediated metabolism of methyleugenol in mouse liver. 
Absence of N
Time course of the levels of the hepatic DNA adducts in mice treated with methyleugenol or 1′-OH-ME
The aim of these experiments was to determine a treatment duration appropriate for comparing adduct levels formed in different mouse lines. The experiments were conducted in tg animals. A first series of mice were killed at varying times (0.75-24 h) after the intraperitoneal administration of 1′-OH-ME. Adduct levels were fairly constant over the entire observation period (Table II) . This result suggests that 1′-OH-ME was activated very rapidly and that adducts were rather resistant to DNA repair. The second experiment involved the oral administration of methyleugenol and killing of the animals 1.5-24 h later. In this experiment, adduct levels were lower at the first analysis time (1.5 h) than at the later times (3-24 h), when a plateau was reached. The delay in the adduct formation compared with the 1′-OH-ME treatment may be owed to the additional hydroxylation step required for the activation of methyleugenol. Moreover, absorption of methyleugenol, given orally, may have taken more time than that of 1′-OH-ME, applied intraperitoneally. Based on these time courses, animals were killed 6 h after the treatment in all subsequent experiments.
We show the results for both adducts, N 6 -MIE-dA and N 2 -MIE-dG, for the time course studies (Table II) . In all treatment groups, the N 2 -MIE-dG was more abundant than N 6 -MIE-dA by a factor of 30-72. Similar findings were made in all other experiments. Therefore, we only present the results for N 2 -MIE-dG in Table III of the main paper. The corresponding results for the minor adduct, N 6 -MIE-dA, are given in Supplementary Table S-III, available at Carcinogenesis Online. The ratios of the N 2 -MIE-dG and N 6 -MIE-dA in the present study were similar to those previously found in SULT-expressing S.typhimurium strains treated with 1′-OH-ME, 31-65 (20) , and human liver biopsy samples, ~60 (25) .
Impact of the SULT status on the formation of hepatic DNA adducts in mice treated with methyleugenol or 1′-OH-ME
Methyleugenol at a dose 50 mg (280 µmol) per kg body mass formed 735 and 23 N 2 -MIE-dG adducts per 10 8 dN in wt and ko mice, respectively (Table III) . Thus, adduct formation was reduced by 97% in the absence of Sult1a1. At the next lower dose (28 µmol/kg), no adducts were detectable in ko animals, whereas 100 N 2 -MIE-dG adducts per 10 8 dN were detected in the wt mice. On the contrary, human SULT1A1/2, alone (ko-tg) or together with mouse Sult1a1 (tg), enhanced the adduct formation strongly, 5-and 6-fold, respectively, above the wt level, at the 280 µmol/kg (Table III) . Similar enhancements were observed at lower doses.
1′-OH-ME induced twice as many adducts as methyleugenol in wt mice, whereas only 12 N 2 -MIE-dG adducts per 10 8 dN were detected in ko mice. Thus, knockout of Sult1a1 decreased the adduct formation by a factor of 120. Therefore, the impact of Sult1a1 was even stronger with 1′-OH-ME than with methyleugenol. The same was true for the enhancement by human SULT1A1/2. N 2 -MIE-dG adduct levels were 8-and 9-fold higher in ko-tg and tg mice, respectively, than in the wt mice. SULTs often compete with uridine 5′-diphospho-glucuronosyltransferases for the same substrates. Sulfation is normally a high-affinity, low-capacity pathway, whereas glucuronidation is characterized by low affinity, but high capacity (34) . Thus, glucuronidation may be favored at bolus exposures, as is the case after direct intraperitoneal administration of the phase-1 metabolite 1′-OH-ME. A high level of SULT enzyme may be particularly important in this situation to enhance the sulfation capacity.
Dose-response relationships for the formation of hepatic DNA adducts by methyleugenol in wt and humanized (ko-tg) mice
Methyleugenol was administered at four different dose levels, covering a 1000-fold range. DNA adducts were detected at the three highest dose levels in wt mice and at all four doses in ko-tg mice (Table III) . Levels of N 2 -MIE-dG adducts were 4-to 6.5-fold higher in ko-tg mice than in wt mice at the individual dose levels. The dose-response relationship was nearly linear in wt mice but appeared somewhat supralinear at low compared with high doses in ko-tg mice.
Anthony et al. (35) studied the biotransformation of [methoxy- Table I . 1, 3,4-dimethoxypropylbenzene (internal standard); 2, methyleugenol; 3, eugenol and chavibetol; 4, 6-hydroxymethyleugenol; 5, methyleugenol-2′,3′-epoxide; 6, unknown metabolite; 7, 3′-hydroxymethylisoeugenol; 8, 1′-hydroxymethyleugenol; 9, 2′,3′-dihydroxy-2′,3′-dihydromethyleugenol.
1′-hydroxyestragole at higher doses (1.3, 2.1, 5.2, 7.8 and 9.4% of the dose at 0.05, 5, 50, 500 and 1000 mg/kg in the mouse; similar values in the rat). Based on this observation, they proposed a dose-dependent metabolic shift in the cytochrome P450-mediated biotransformation pathways with predominance of demethylation (detoxification) at low doses and increase in 1′-hydroxylation (toxification) at high doses. Moreover, conjugates of 1′-hydroxysafrole were observed in urine of rats, but not humans, both exposed to [ 14 C]safrole at a dose of 0.6 mg/ kg (36) . This metabolic shift and the apparent absence (of glucuronides) of 1′-hydroxylated metabolites of alkenylbenzenes have been used as major reasons to postulate 'that present exposure to methyl eugenol and estragole resulting from consumption of food, mainly spices and added as such, does not pose a significant cancer risk' (37). It is difficult to sustain this concept for methyleugenol. We found in our preceding study that DNA adducts of this alkenylbenzene are abundant in human liver specimens. And the present experimental study provides no indication for a dose-dependent metabolic shift; even it occurred, it did not manifest in decreased adduct formation, per dose unit, at low exposure levels. Of course, the situation may differ between different alkenylbenzenes. Moreover, we suspect that urinary excretion of glucuronides of 1′-hydroxylated metabolites is a problematic biomarker for estimating the extent of bioactivation of alkenylbenzenes. Many xenobiotics are preferentially sulfated at low doses with a shift toward glucuronidation at higher exposures (34) . Therefore, low levels of urinary glucuronides of 1′-hydroxyalkenylbenzenes could either indicate a low level of 1′-hydroxylation (first step of activation), a high level of sulfation (second step of activation) or a combination of both. 19.6 ± 6.3 24.9 ± 3.9 24.2 ± 10.9 3′-OH-MIE 6.0 ± 0.7 3.9 ± 1.1 5.8 ± 1.7 5.7 ± 2.3 6-Hydroxymethyleugenol 6.1 ± 0.9 5.2 ± 1.7 2.8 ± 1.7 5.6 ± 2.6 2′,3′-Dihydroxy-2′,3′-dihydromethyleugenol 6.9 ± 1.2 4.1 ± 1.3 5.9 ± 2.0 5.3 ± 2.4
Eugenol + chavibetol 2.1 ± 0.2 1.7 ± 0.3 1.9 ± 0.3 1.8 ± 0.5 Methyleugenol-2′,3′-epoxide 3.5 ± 1.1 2.9 ± 1.4 2.8 ± 0.4 2.3 ± 0.7 Sum of recovered material 160.6 ± 10.5 161.7 ± 11.7 151.9 ± 11.8 155.9 ± 13.0 a Methyleugenol (200 µM) was incubated with hepatic microsomes (1 mg/ml protein) and a system generating reduced nicotinamide adenine dinucleotide phosphate at 37°C for 1 h. The metabolites were determined by high-performance liquid chromatography with ultraviolet detection, using chemically synthesized metabolite standards for the assignments and the calibration. Values are mean ± SD of four incubations, using microsomal preparation from separate animals. The structural formulas of the analytes and representative chromatograms are shown in Figures 1 and 2 , respectively. Methyleugenol (50 mg/kg body mass) was orally administered. An equimolar dose of 1′-OH-ME (280 µmol/kg body mass) was given intraperitoneally. Animals were killed at varying times after treatment. DNA was enzymatically digested to nucleosides, followed by adduct analysis using isotope-dilution liquid chromatography-tandem mass spectrometry. Values are mean ± half range of two animals per group. n.i., not investigated. a Animals were killed 6 h after the oral administration of methyleugenol or the intraperitoneal administration of 1′-OH-ME. DNA was enzymatically digested to nucleosides, followed by adduct analysis using isotope-dilution liquid chromatography-tandem mass spectrometry. Values are mean ± SD of four animals. They are only given, if at least three out of the four animals showed adducts levels > LOD. Otherwise the LOD is given (30 and 6 adducts per 10 8 dN using the standard and enhanced method, respectively). n.i., not investigated. Levels of the minor adduct, N 6 -MIE-dA (presented in Supplementary Table S-III, available at Carcinogenesis Online), were nearly 1/50 of those of the N Dose-response relationships of alkenylbenzenes were also addressed in other studies. Gupta et al. (32) investigated the formation of DNA adducts by safrole in mouse liver over a 10 000-fold dose range (0.001-10 mg per mouse) using a sensitive version of the 32 P-post-labeling assay. Their dose-response curve was nearly linear, similar to the one observed in our study with methyleugenol in wt mice. Likewise, physiologically based kinetic models, developed by Al-Subeihi et al. (38) , predict that formation of the reactive sulfooxy metabolites and DNA adducts by methyleugenol is linear from dose levels as low as common human exposures up to levels causing tumor formation in animal models.
Adduct formation by methylisoeugenol and 3′-OH-MIE in humanized (ko-tg) mice
3′-OH-MIE was equally mutagenic to 1′-OH-ME in Salmonella strains expressing human SULT1A1, human SULT1A2 or mouse Sult1a1 (20) . 3′-OH-MIE is usually formed at lower levels from methyleugenol than its isomer 1′-OH-ME (ref. 29 , Table I ). However, 3′-OH-MIE is a major metabolite of methylisoeugenol (27, 28) . For these reasons, we also investigated methylisoeugenol and 3′-OH-MIE on formation of hepatic DNA adducts in humanized (ko-tg) mice. At a dose of 280 µmol/kg body mass, adducts were detectable when the enhanced assay was used (Table IV) . Methylisoeugenol formed 30 ± 5 N 2 -MIE-dG adducts per 10 8 dN, which is nearly 1% of the level induced by an equimolar dose of methyleugenol. 3′-OH-MIE-treated animals showed 17 ± 4 N 2 -MIE-dG adducts per 10 8 dN, approximately 0.14% of the level observed with an equimolar dose of its isomer, 1′-OH-ME. These findings suggest an important role of detoxifying pathways for 3′-OH-MIE. This is supported by the report that methylisoeugenol is preferentially oxidized in the 3′ position, leading to cinnamic acid derivatives and, after side-chain shortening, to benzoic acid derivatives (28) .
Conclusions
Various alkenylbenzenes are genotoxic hepatocarcinogens in rat and mouse models but are negative in standard in vitro genotoxicity tests, such as the Ames assay, even if S9 postmitochondrial fraction from a target tissue, rat liver, is used as an activating system (39, 40) . The reason is trivial, as SULTs are involved in the bioactivation. These enzymes are inactive in S9 preparations due to the lack of the cosubstrate, 3′-phosphoadenosine-5′-phosphosulfate; and even if this cosubstrate is supplemented, extracellularly formed reactive sulfo conjugates may not penetrate into the target cell (41) . However, hydroxylated metabolites of alkenylbenzenes are mutagenic in bacteria, when appropriate SULTs are expressed in the target cells (20) . Somewhat surprisingly, 1′-OH-ME and 3′-OH-MIE showed comparable activities in these systems. However, 3′-OH-MIE formed ~700-fold lower adduct levels compared with 1′-OH-ME in ko-tg mice (Tables III and IV) . The low activity in vivo appears to be due to efficient sequestration by oxidative metabolism, mediated by alcohol and aldehyde dehydrogenases (R.Kollock and H.Glatt, unpublished result). Again the required cofactor, oxidized nicotinamide adenine dinucleotide, is missing in standard S9 preparations. Thus, the fixation of standard activating systems to cytochrome P450 activities and the neglect of other enzymes can lead not only to false-negative results but also to false-(or excessively) positive results. The alkenylbenzenes and their metabolites provide good examples for both situations.
For these reasons, we sought to explore the role of SULT1A enzymes in the genotoxicity of methyleugenol in vivo in mouse liver, a known target organ of carcinogenicity. Impressively, knockout of a single Sult gene, Sult1a1, abolished DNA adduct formation by methyleugenol and 1′-OH-ME by ≥97%. This result was surprising, as the mouse genome contains at least 15 transcribed Sult genes, and most of them are expressed in the liver (23, (42) (43) (44) (and unpublished data from W.M. and H.G.). Replacement of mouse Sult1a1 by the human SULT1A1/2 cluster led to pronounced enhancement of the DNA adduct formation in our model. This finding is in agreement with our previous results with recombinant Salmonella strains. Human SULT1A1 activated 1′-OH-ME more efficiently than its mouse ortholog (20) . Nevertheless, some precaution is required regarding the mouse model studied, as the tg mice have nearly 43 copies of the SULT1A1/2 cluster in their genome, and the hepatic level of SULT1A1 reaches 4.3% of the cytosolic protein (26) . In humans, a copy number polymorphism of SULT1A1 has been detected (45) .
One to approximately five SULT1A1 copies had been found in 461 subjects (Caucasian-Americans and African-Americans) (45) . Riches et al. (21) estimated the mean SULT1A1 level in 28 human liver specimens to 0.32% of the cytosolic protein. The extreme predominance of a single SULT form in the activation of methyleugenol, at least in mouse liver, may facilitate the development of physiologically based toxicokinetic models to estimate the impact of species differences, genetic polymorphisms and drug-drug interactions, as proposed by the group of I.Rietjens (38, 46, 47) .
A single dose of 0.05 mg/kg (0.28 µmol/kg) methyleugenol was sufficient to form detectable levels of DNA adducts in the liver of ko-tg mice. This dose is 4-fold below the estimated mean daily intake of methyleugenol by humans from foods (3). In agreement with this efficiency in adduct formation even at low doses, we were able to clearly demonstrate the presence of N 2 -MIE-dG adducts, and often also N 6 -MIE-dA adducts, in 29 out of 30 human liver biopsy specimens studied (25) . Based on the results in the mouse lines with varying SULT1A status, it is obvious to expect that individual variation in the SULT1A1 level, e.g. due to copy number polymorphism, may affect the susceptibility.
Supplementary Material
Supplementary Tables SI-SIII can be found at http://carcin.oxfordjournals.org/
Funding
German Federal Institute for Risk Assessment, Berlin, Germany (FK-3-1329.421.1+2). Methylisoeugenol and 3′-OH-MIE were administered orally and intraperitoneally, respectively, as their isomers methyleugenol and 1′-OH-ME (Table III) . Animals were killed 6 h after treatment. All analyses were carried out with the enhanced protocol. Values are mean ± SD of four animals. They are only given, if at least three out of the four animals showed adducts levels > LOD. Otherwise the LOD (6 N 2 -MIE-dG or 0.6 N 6 -MIE-dA per 10 8 dN) is given.
